HC Wainwright Reaffirms “Buy” Rating for Tango Therapeutics (NASDAQ:TNGX)

Posted by Francis Steltz on Oct 29th, 2026

Tango Therapeutics (NASDAQ:TNGX – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $68.00 target price on the stock. HC Wainwright‘s price objective suggests a potential upside of 205.89% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on TNGX. Mizuho upped their price target on shares of Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Stifel Nicolaus set a $55.00 price objective on shares of Tango Therapeutics in a research note on Friday, October 23rd. Weiss Ratings upgraded shares of Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Guggenheim upped their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, William Blair assumed coverage on Tango Therapeutics in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.62.

Read Our Latest Research Report on Tango Therapeutics

Tango Therapeutics Price Performance

NASDAQ TNGX opened at $22.23 on Thursday. Tango Therapeutics has a 1-year low of $7.37 and a 1-year high of $34.39. The business has a 50 day simple moving average of $23.67 and a two-hundred day simple moving average of $22.11. The stock has a market capitalization of $3.75 billion, a PE ratio of -26.15 and a beta of 1.17.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, analysts anticipate that Tango Therapeutics will post -1.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $24.47, for a total transaction of $660,690.00. Following the completion of the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at $2,832,231.21. The trade was a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jessica Newcomb sold 8,200 shares of Tango Therapeutics stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total transaction of $198,604.00. Following the transaction, the insider directly owned 59,121 shares of the company’s stock, valued at $1,431,910.62. The trade was a 12.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 6.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tango Therapeutics

Large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Tango Therapeutics during the third quarter worth $215,000. Profund Advisors LLC boosted its stake in shares of Tango Therapeutics by 48.8% during the third quarter. Profund Advisors LLC now owns 62,319 shares of the company’s stock valued at $1,555,000 after purchasing an additional 20,430 shares during the period. Vise Technologies Inc. bought a new position in shares of Tango Therapeutics in the third quarter worth about $319,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Tango Therapeutics by 28.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 37,165 shares of the company’s stock worth $908,000 after purchasing an additional 8,144 shares during the last quarter. Finally, Sterling Capital Management LLC increased its stake in Tango Therapeutics by 838.8% in the 3rd quarter. Sterling Capital Management LLC now owns 4,647 shares of the company’s stock worth $116,000 after buying an additional 4,152 shares during the period. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.